Search Results

Lipocine Inc. today announced that commercialization of TLANDO® in the U.S. has been transitioned to its licensee Verity Pharma, effective February 1, 2024 , enabling the continuity of patient access to TLANDO.

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, Gordon Silver Limited and Verity Pharmaceuticals, Inc. (Verity Pharma) today announced that they have entered into an exclusive licensing agreement under which Verity Pharma will market TLANDO® in the United States and, if approved, in Canada.

Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced the signing of an agreement with Verity Pharmaceuticals (“Verity Pharma”) for the exclusive rights to promote NATESTO in Puerto Rico.

Specialty pharmaceutical company Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it has entered into a national co-promotion agreement with Verity Pharmaceuticals International Ltd. to support Cumberland’s new Sancuso® oncology support product.

Verity Pharmaceuticals ™ and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico.

Cipher Pharmaceuticals Inc. (TSX: CPH)today announced it has entered into an exclusive co-promotion agreement with Verity Pharmaceuticals Inc. for the marketing, sales and co-promotion of Brinavess, Aggrastat and Trevyent.